• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Long-term Survival of Severe Trauma Patients Treated with Tranexamic Acid

June 21, 2023

Globally, trauma is the leading cause of death for young people.  In 2011, the World Health Organization added tranexamic acid to the Model List of Essential Medicines for the treatment of trauma based on randomized trial data showing that tranexamic acid reduces mortality of hemorrhaging trauma patients.  Some data have suggested that tranexamic acid should be administered within 3 hours after injury to be most effective.  To explore the effect of tranexamic acid on the quality of survival, the Pre-hospital Antifibrinolytics for Traumatic Coagulopathy and Hemorrhage (PATCH-Trauma) trial randomized a total of 1310 severe trauma patients at risk for trauma-induced coagulopathy to receive either tranexamic acid (1 g before hospital admission followed by 1 g after arrival at the hospital) or placebo at 15 emergency medical centers in Australia, New Zealand, and Germany.  Overall, 19.0% (123/648) of patients in the tranexamic acid arm died six months after injury compared to 22.0% (144/629) in the placebo arm.  Survival without severe disability, however, was similar in both groups (53.7% vs. 53.5%, respectively) as were adverse events.  Further data is needed on tranexamic acid use in other subgroups of patients including less severe trauma patients with more potential for good recovery.

References:

  1. The PATCH-Trauma Investigators and the ANZICS Clinical Trials Group.  Prehospital tranexamic acid for severe trauma.  The New England Journal of Medicine 2023
  2. Shakur-Still and I. Roberts. Tranexamic acid for trauma patients—more lives to save and outcomes to consider.  The New England Journal of Medicine 2023     

Filed Under

  • News
  • Special Transfusion Situations

Recommended

  • FDA Approves Babesia microti Screen for Plasma and Whole Blood Donations

  • Anti-CD19 CAR-T Cells as First-Line Therapy for High-Risk Large B-Cell Lymphoma

  • AABB Clinical Practice Guidelines for RBC Transfusions

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Blood Donation Teams—a Novel Strategy to Support Novice Donors

  • Plasma Exchange to Reduce Biological Age

  • New Guidelines for Platelet Transfusion Recommend Restrictive Strategies

  • Directed Blood Donations Should be Limited

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley